Rsv case study emma
From: Michael G.
Category: engelsk essay
Share this post:
Almost all children get RSV at least once before they are 2 years old. For most healthy children, RSV is like a cold. But, some children get very sick with RSV. This virus occurs in the late fall through early spring months. Typically, RSV causes a cold , which may be followed by bronchiolitis or pneumonia. Symptoms generally last an average of days.
Michelle Carlo, 22, Columbus, Indiana. Thanks for the paper containing accurate data and reliable material. I couldnt structure my paper so well as you did.
RSV Infection in the Immunocompromised Host
Preventing and treating RSV pneumonia in immunocompromised cancer patients | sustentabilidade.info
The surveillance reports provide a wealth of epidemiological data to support decision-making at the national level. With the new tools, public health experts can detect possible outbreaks or draft epidemiological reports. ECDC collects, analyses and disseminates surveillance data on communicable diseases and related special health issues. Regular reporting on epidemiological cases is introduced for some disease threats, such as influenza, West Nile fever, measles.
Lydia Domingues, 27, Harvey Cedars, New Jersey. Just checking in to say a thank-you! Youre good at what Im not - writing. Weve been a perfect team for two years and I thoroughly enjoyed the experience.
Respiratory Syncytial Virus (RSV)
The risk of mortality increases as the infection progresses from the upper respiratory tract to the lower respiratory tract. Prompt identification of the underlying disease and timely initiation of treatment are prudent. Although the optimal treatment for RSV infection in the immunocompromised patient has not been clearly defined, a combination of aerosolized ribavirin with an immunomodulator should be considered.
The guideline covers the clinical development of vaccines and monoclonal antibodies for the prevention of RSV disease and direct acting antiviral agents DAAs for the treatment of RSV disease. The focus is on the assessment of safety and efficacy in populations most likely to develop RSV lower respiratory tract infection and severe RSV disease, including newborn infants and toddlers, older paediatric subjects predisposed to develop severe RSV disease and the elderly. The guideline also addresses vaccination of pregnant women with the aim of preventing RSV disease in their infants. Some considerations are proposed on nonclinical investigations of efficacy and risk of vaccine-associated enhanced disease to support clinical trials with preventive or therapeutic products directed at RSV. Keywords: Respiratory syncytial virus, bronchiolitis, severe RSV disease, case definition, clinical and laboratory confirmation, vaccine-associated disease enhancement, vaccination of pregnant women, monoclonal antibodies, direct acting antiviral agents, rapid diagnostic tests.